secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0000950170-25-038015
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista Q3 fiscal 2025: $253.2M cash, sebetralstat regulatory progress; PDUFA June 17
--------------------------------------------------------------------------------

- No revenue; R&D expense $12.6M (down from $22.5M YoY); G&A $30.3M (up from $10.6M) due to pre-commercial activities.
- Cash, cash equivalents and marketable securities of $253.2M as of Jan 31, 2025.
- Sebetralstat NDA submitted in Japan, orphan drug designation granted; U.S. PDUFA date June 17, 2025.
- Raised $160M gross proceeds in Nov 2024 via synthetic royalty financing and equity offerings to fund launch.
- Field sales team onboarded; Jeb Ledell appointed COO; new data presented on laryngeal attacks, adolescents, and LTP patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017025038015/0000950170-25-038015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017025038015/kalv-20250312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-038015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer